Open an account

Precigen

PGEN · NASDAQ

$6.83+$0.17 (+2.55%)TodayMarket closed ·
Prev close $6.66

PGEN analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy3
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 5 analysts

Average $13.94 (+104.1% upside)

Low
$11.11
Now
$6.83
High
$18.90

Upgrades and downgrades

The latest rating actions, newest first

PGEN analyst upgrades, downgrades and rating actions
FirmDateActionRating
B. Riley SecuritiesSep 25, 2026InitiatesBuy
HC Wainwright & Co.Aug 5, 2026MaintainsBuy
HC Wainwright & Co.Aug 3, 2026MaintainsBuy
HC Wainwright & Co.May 28, 2026MaintainsBuy
CitizensMay 14, 2026MaintainsMarket Outperform
HC Wainwright & Co.May 14, 2026MaintainsBuy
CitizensMar 26, 2026MaintainsMarket Outperform
HC Wainwright & Co.Mar 26, 2026MaintainsBuy
HC Wainwright & Co.Nov 14, 2025MaintainsBuy

The case for and against

Updated Oct 14, 2026

Bull case

Precigen is attractive because PAPZIMEOS is the first and only FDA-approved therapy for adult recurrent respiratory papillomatosis, giving it a first-mover advantage in a rare disease where patients otherwise rely on repeated surgical debulking. Its launch is already showing strong traction, with $21.6M in 1Q26 revenue and $53.1M in its second full quarter, while durable efficacy remains compelling as 83% of complete responders were still maintained after at least three years and five responses have lasted more than four years. Beyond PAPZIMEOS, the AdenoVerse platform received FDA Platform Technology Designation on September 21, 2026, and PRGN-2009 plus pembrolizumab is nearing an early 4Q26 update, supporting a broader multi-asset pipeline with meaningful upside optionality.

Bear case

Precigen is weighed down by a pipeline that remains largely clinical-stage, with PRGN-2009 assigned only a 20% probability of success and modeled to reach just $37M in worldwide revenue in 2035 despite an assumed ~$80k therapy cost. Its broader programs also face meaningful execution risk, as management cites enrollment disruptions, possible efficacy or safety shortfalls, and regulatory uncertainty around approval pathways that could delay commercialization. Financially, the company is capital-intensive and dependent on external funding, so any unfavorable financing could be dilutive, while the shrinking juvenile-onset RRP opportunity and IP vulnerability further weaken the fundamental outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.